Résumé
BackgroundAntimicrobial resistance (AMR) in Enterobacterales is a growing concern in sub-Saharan Africa, yet data remain scarce for Central Africa.MethodsWe conducted a systematic review and meta-analysis (2008-2024) to estimate the prevalence of extended spectrum ss-lactamase-producing Enterobacterales (ESBL-EB) and AMR frequency across nine Central African countries. Systematic searching strategy and risk of bias assessment followed PRISMA guidelines. Prevalence or frequencies and 95% confidence intervals were estimated using a random effects meta-model with the Der Simonian and Laird method.ResultsHere we show an ESBL-EB pooled prevalence of 22% (41% for carriage and 10% in clinical samples) for the 24 selected articles assessing ESBL-EB. For the 26 selected articles assessing AMR frequency, we find it is high for cotrimoxazole (63-81%), amoxicillin/clavulanic acid (43-63%), ciprofloxacin (24-33%), and remains lower for nitrofurantoin (12-18%) and amikacin (13-19%). We provide pooled estimates for alternative agents and highlight the near-total absence of data for WHO Reserve antibiotics, including carbapenems, newer beta-lactam/beta-lactamase inhibitors, and fosfomycin. Significant heterogeneity and high exclusion rate due to risk of bias reflect major diagnostic limitations in the region.ConclusionsThe high prevalence of AMR in Central Africa underscores the urgent need to strengthen antimicrobial susceptibility testing capacities, restrict empirical use of key antibiotics, and ensure equitable access to effective antimicrobials. Without coordinated investments for microbiology capacities scale-up, prescription regulation, strategies for water, sanitation and hygiene, and infection prevention and control, patient outcomes and regional AMR containment will be jeopardized.